Compare · AVBP vs NVO
AVBP vs NVO
Side-by-side comparison of ArriVent BioPharma Inc. (AVBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $204.85B, about 134.5x AVBP ($1.52B).
- Over the past year, AVBP is up 43.3% and NVO is down 34.2% - AVBP leads by 77.5 points.
- AVBP has been more active in the news (5 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for AVBP).
- Company
- ArriVent BioPharma Inc.
- Novo Nordisk A/S
- Price
- $32.69+3.06%
- $45.89+6.25%
- Market cap
- $1.52B
- $204.85B
- 1M return
- +20.10%
- +1.81%
- 1Y return
- +43.28%
- -34.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 3
- Recent ratings
- 11
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVBP
- SEC Form 4 filed by Director Parsey Merdad
- SEC Form 4 filed by Director Peterson Kristine
- SEC Form 4 filed by Director Hohneker John
- SEC Form 4 filed by Director Nolet Chris
- ArriVent BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- ArriVent BioPharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by ArriVent BioPharma Inc.
- SEC Form 10-Q filed by ArriVent BioPharma Inc.
- ArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ArriVent BioPharma Reports First Quarter 2026 Financial Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S